Targeting Tear Evaporation: How Perfluorohexyloctane Ophthalmic Solution Redefines the Management of Evaporative Dry Eye Disease

Listen

0:00 / 0:00

This clinical brief is supported by Bausch + Lomb.

This AJMC® Clinical Brief provides a primer on dry eye disease (DED) diagnosis, pathophysiology, and treatment, highlights a DED treatment, and discusses real-world data about patient treatment satisfaction.

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe Now!

Latest CME

Online Article

Innovations in Medicine: 2024 Lineup of New and Approved Specialty Drugs

2.0 Credits / General Pharmacy

AJMC Supplement

Revolutionizing Acute Pain Relief: Emerging Nonopioid Therapies and the Essential Role of Managed Care

2.0 Credits / Pain Management

Targeting Tear Evaporation: How Perfluorohexyloctane Ophthalmic Solution Redefines the Management of Evaporative Dry Eye Disease

Newsletter

Related Content

FAQs About Glaucoma as Awareness Month Concludes

Strong Patient–Doctor Communication Improves Glaucoma Care: Ariana Levin, MD

Vision Rehabilitation Can Help Patients Unable to Prevent Vision Loss in Glaucoma: Jullia Rosdahl, MD, PhD

Glaucoma Awareness Month Shines Light on Eye Condition Known as the Silent Thief

Treatment for Glaucoma Continues to Evolve, Allowing Eye Doctors to Personalize Treatment: Manjool Shah, MD

Latest CME

Innovations in Medicine: 2024 Lineup of New and Approved Specialty Drugs

Revolutionizing Acute Pain Relief: Emerging Nonopioid Therapies and the Essential Role of Managed Care

Trending on AJMC

TrumpRx Launch Brings Savings—and Uncertainty

How Do GLP-1 Agonists Fit Into Stroke Care?

Addressing Disparities at Every Step of the Stroke Care Pathway: Luke Messac, MD, PhD

Aligning Treatment Goals in IgA Nephropathy: Applying KDIGO’s Dual-Pathway Framework to Clinical Decision-Making

5 Things to Know About the Oral GLP-1 Era